Amyotrophic Lateral Sclerosis (ALS), Spinal and Bulbar Muscular Atrophy, Hereditary Spastic Paraplegia, Friedreich’s Ataxia
Dr. Amelie Gubitz serves as a Program Director in the Neurodegeneration Cluster of the Division of Neuroscience. Her portfolio includes basic, translational and clinical research on amyotrophic lateral sclerosis, X-linked spinal and bulbar muscular atrophy, hereditary spastic paraplegia and Friedreich's ataxia. Dr. Gubitz earned a Ph.D. in pharmacology from the University of Cambridge, UK, and then completed a Wellcome Trust Fellowship at Harvard Medical School in circadian biology. She has also worked as a Senior Scientist in the target discovery group for neuropathic pain at Parke Davis, UK, and as a Research Assistant Professor at the University of Pennsylvania where she studied the molecular pathogenesis of spinal muscular atrophy.